Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Posted by Francis Steltz on May 23rd, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $18.99, but opened at $20.49. Ascentage Pharma Group International shares last traded at $20.4250, with a volume of 1,047 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Finally, China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus price target of $46.67.

View Our Latest Research Report on Ascentage Pharma Group International

Ascentage Pharma Group International Price Performance

The stock’s fifty day moving average is $23.45 and its 200 day moving average is $26.21. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million during the quarter. Equities research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International in the third quarter worth about $96,000. ABC Arbitrage SA bought a new stake in Ascentage Pharma Group International during the 3rd quarter valued at approximately $204,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000. Finally, UBS Group AG raised its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.